Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

T Cell Types and Functions01:24

T Cell Types and Functions

1.4K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

230
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
230
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

264
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
264
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

360
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
360
The Tumor Microenvironment02:17

The Tumor Microenvironment

6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Regulatory T cells in cancer anti-PD-(L)1 therapy.

Human cell·2025
Same author

Selective targeting or reprogramming of intra-tumoral Tregs.

Medical oncology (Northwood, London, England)·2024
Same author

An Update of Extracellular Vesicle Involvement in Different Steps of Cancer Metastasis and Targeting Strategies.

Current medicinal chemistry·2024
Same author

Extracellular vesicle-based drug delivery in cancer immunotherapy.

Drug delivery and translational research·2023
Same author

The impact of hypoxia on extracellular vesicle secretome profile of cancer.

Medical oncology (Northwood, London, England)·2023
Same author

Transforming growth factor-β signalling in tumour resistance to the anti-PD-(L)1 therapy: Updated.

Journal of cellular and molecular medicine·2023

相关实验视频

Updated: Sep 8, 2025

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

2.7K

微生物群与Tregs的相互作用:大肠炎的目标

Keywan Mortezaee1,2

  • 1Department of Anatomy, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran. keywan987@yahoo.com.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|June 26, 2025
PubMed
概括

肠道微生物群影响调节性T细胞 (Tregs) 维持免疫平衡,防止肠道炎症. 利用这种微生物组-Treg相互作用,特别是通过便微生物移植 (FMT),为结肠炎提供了一个有前途的治疗策略.

关键词:
大肠炎是一种炎症.便微生物移植 (FMT) 方法微生物群中的微生物群监管性T细胞 (Treg) 是一种T细胞.短链脂肪酸 (SCFA) 是一种短链脂肪酸.

更多相关视频

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.0K
Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
06:57

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

9.1K

相关实验视频

Last Updated: Sep 8, 2025

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

2.7K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.0K
Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
06:57

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

9.1K

科学领域:

  • 免疫学 免疫学 免疫学
  • 微生物学 微生物学
  • 胃肠病学 胃肠病学

背景情况:

  • 肠道微生物群和调节性T细胞 (Tregs) 对免疫平衡和预防炎症至关重要.
  • Tregs具有免疫抑制活性,对于维持肠道健康和限制炎症反应至关重要.
  • 失生症和降低的Treg功能与炎症性肠道疾病 (如结肠炎) 有关.

研究的目的:

  • 在肠道炎症的背景下,审查肠道微生物群对Tregs的影响.
  • 探索涉及微生物组与Treg相互作用的治疗策略,以治疗大肠炎.
  • 了解这种相互作用在癌症免疫疗法诱导的大肠炎中的作用.

主要方法:

  • 文献综述侧重于肠道炎症中的微生物组-Treg相互作用.
  • 微生物代谢物的分析,如短链脂肪酸 (SCFA),以及它们对Treg分化的影响.
  • 检查便微生物移植 (FMT) 作为大肠炎的治疗方法.

主要成果:

  • 微生物SCFA促进Treg生成和维护,抵消肠道炎症.
  • 诱导Treg会影响肠道微生物群的组成,增强宿主保护.
  • 便微生物移植 (FMT) 可以恢复Treg种群和肠道屏障功能,改善结肠炎.

结论:

  • 调节Treg-微生物群相互作用,包括Treg重编程和FMT,为结肠炎提供了一个可行的治疗途径.
  • FMT可以通过促进Tregs和有益的微生物来恢复免疫平衡,即使在接受免疫治疗的癌症患者中也是如此.
  • 了解Treg-微生物组轴是开发新型炎症病治疗方法的关键.